Description: Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Home Page: www.apellis.com
APLS Technical Analysis
100 Fifth Avenue
Waltham,
MA
02451
United States
Phone:
617 977 5700
Officers
| Name | Title |
|---|---|
| Dr. Cedric Francois M.D., Ph.D. | Co-Founder, Pres, CEO & Director |
| Dr. Pascal Deschatelets Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Federico Grossi M.D., Ph.D. | Co-Founder & Chief Medical Officer |
| Mr. Alec Machiels J.D., MBA | Co-Founder & Director |
| Mr. Timothy E. Sullivan | CFO & Treasurer |
| Mr. Adam J. Townsend | Chief Commercial Officer |
| Ms. Nur Nicholson | Chief Technical Operations Officer |
| Mr. James G. Chopas CPA | VP, Corp. Controller & Chief Accounting Officer |
| Ms. Meredith Kaya | Sr. VP, Investor Relations & Strategic Fin. |
| Mr. David O. Watson Esq., J.D. | Gen. Counsel |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 17.6717 |
| Price-to-Sales TTM: | 51.2635 |
| IPO Date: | 2017-11-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 476 |